OpenAI president Greg Brockman says AI will deliver significant progress in biology, health and disease within the next 12 to 18 months. He spoke with Wall Street Journal reporter Keach Hagey at WSJ Tech in Napa on 4 November. In the same conversation, he raised the possibility that death could one day become “a choice,” but he gave no timeline for that idea.
A clip of the remark spread on X the next morning. Many replies argued that ending death doesn’t belong on a product roadmap.
Research Speed vs. Approved Treatments
In April, OpenAI launched GPT-Rosalind, a reasoning model for biology and drug discovery. Its partners include Amgen, Moderna, Thermo Fisher Scientific, and the Allen Institute. Models like this mostly help with early research, such as literature reviews and experiment planning. OpenAI has said that U.S. drugs usually take 10 to 15 years to go from target discovery to approval, and most of that time is spent on clinical trials and regulatory review.
IPO Plans and Business Growth
Brockman also said the first half of 2026 was difficult for OpenAI, as Anthropic gained ground with business customers. He said annualised revenue grew 70% from the second quarter to the third, and that enterprise customers now make up the majority of revenue. Asked whether OpenAI could be ready for an IPO in 2027, he said he thought so. He also admitted the industry was surprised by the backlash against data centres in the U.S. midterm elections.
What It Means for Businesses
State of AI argues that companies should read the 18-month prediction as a forecast about research speed, not about treatments reaching patients. It also suggests asking AI vendors for the data behind their claims.
Source: State of AI
Originally Published: 5 November 2026
